Myeloproliferative diseases are a heterogeneous group of conditions characterized by excessive cellular proliferation of one or more types of peripheral blood cells. Allogenic haematopoietic stem ...

Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers involving the uncontrolled replication of cells derived from myeloid stem cells.

Myeloproliferative disorders include several different conditions that are characterized by excess production of blood cells in the body. They differ based on which type of blood cell is ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

What is the difference between leukemia and myeloproliferative disorders? In both diseases, the abnormal cancer cells start in the bone marrow. Myeloproliferative disorders produce mature cells ...

Starting with your first appointment (and after), we are here to answer your questions. We want to help you understand as much as you want to know about your disease, your treatment and how care ...

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality ...

Two recent studies from researchers at Washington University School of Medicine in St. Louis have identified a promising way ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

Dr. Rachel Salit is a hematologist and oncologist, and member of the stem cell transplant faculty at Fred Hutch who focuses on improving stem cell transplant outcomes for patients who have ...